Parmax Pharma Board Approves Shifting Registered Office, Enhancing Borrowing Limits

Parmax Pharma Ltd's Board of Directors approved several key agendas during their meeting on November 14, 2026. The company will shift its registered office from Gujarat to Maharashtra, subject to shareholder approval. Additionally, the board approved enhancing borrowing limits to ₹50 crores under Section 180(1)(a) and Section 180(1)(c) of the Companies Act, 2013, also requiring shareholder consent. The appointment of M/s. Bakul V. Ganatra & Co as Internal Auditor for FY 2026-27 was also approved. The consideration of Un-audited Financial Results for the quarter and half-year ended September 30, 2026, was adjourned.